Skip to main content
Premium Trial:

Request an Annual Quote

Geneus 4.0, MDS42recA Competent Cells

GenoLogics has released Geneus 4.0, a new version of its lab and data management system for genomics research. According to the company, Geneus 4.0 can manage sequencing data from Illumina, ABI, Roche, and other vendors. Also, as a member of Illumina’s Connect bioinformatics partnership program, the company is now able to integrate sequencing-based workflows from Illumina’s Genome Analyzer into its system. Geneus is part of GenoLogics’ Solutions for Research Informatics, which enable data from different science workflows and across multiple labs to be tracked, captured, and stored in a single lab and data management system.

Scarab Genomics has launched MDS42recA competent E. coli cells. The company has improved its Multiple Deletion Strain 42 competent cell line by removing the recA gene from the E. coli genome. As a result, the overall stability of the MDS42 genome and of introduced plasmids is increased, and transformation efficiencies and protein expression are improved, according to Scarab.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.